- Novel guidelines from the National Comprehensive Cancer Network (NCCN) on pediatric acute lymphoblastic leukemia (ALL) place strong emphasis on supportive care interventions for reduction of severe adverse effects and incorporate a number of novel regimens.
Why this matters
- Advances including targeted therapy, immunotherapy, and the approval of chimeric antigen receptor (CAR) T-cell therapy have increased cure rate to approximately 90%, reducing the number of patients in clinical trials.
- NCCN guidelines have increasingly attained global reach.
- Supportive care interventions have been given greater focus to reduce burden of severe adverse effects during treatment, as well as late effects.
- The new guidelines provide advice on best supportive care in vulnerable subpopulations such as very young infants and children with Down syndrome.
- A number of novel treatment strategies have been included such as targeted therapies and CAR T-cell therapy.
- The new guidelines have been designed to span patient ages from birth through young adulthood, and to overlap with guidelines for adults, fostering treatment harmonization in the overlapping age range.
- In response to the increasing global reach of these guidelines, future revisions will also cover best practices applicable in low- and middle-income countries.